Home › Mieloma multiplo › Alabama › Birmingham
Studi clinici su Mieloma multiplo a Birmingham, AL
18 studi su Mieloma multiplo cercano partecipanti presso sedi a Birmingham e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
In reclutamentoFase 1/2
- University of Alabama At Birmingham Hospital, Birmingham
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 3
- Alabama Oncology, Birmingham
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 2
- University of Alabama Birmingham, Birmingham
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 1/2
- University of Alabama at Birmingham Hospital, Birmingham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
In reclutamentoFase 2
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
In reclutamentoFase 3
- University of Alabama at Birmingham, Birmingham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 2
- University of Alabama at Birmingham, Birmingham
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
In reclutamentoFase 1/2
- University of Alabama at Birmingham, Birmingham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
In reclutamentoFase 1/2
- Research Site, Birmingham
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
In reclutamentoFase 1
- University of Alabama at Birmingham, Birmingham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
In reclutamentoFase 2
- University of Alabama at Birmingham, Birmingham
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
In reclutamentoFase 1
- University of Alabama at Birmingham, Birmingham
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
In reclutamentoFase 1
- University of Alabama at Birmingham, Birmingham
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
In reclutamentoFase 2
- University of Alabama at Birmingham, Birmingham
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
In reclutamento
- Kirklin Clinic of UAB Hospital, Birmingham
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
In reclutamentoStudio osservazionale
- Kirklin Clinic of UAB Hospital, Birmingham
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
In reclutamentoFase 1
- University of Alabama at Birmingham, Birmingham
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 1/2
- UAB Comprehensive Cancer Center, Birmingham
Studi su Mieloma multiplo in altre città
- New York City, NY60 studi
- Boston, MA42 studi
- Atlanta, GA41 studi
- Houston, TX38 studi
- Durham, NC37 studi
- Nashville, TN32 studi
- Denver, CO27 studi
- Rochester, MN24 studi
- St. Louis, MO24 studi
- Columbus, OH24 studi
- Baldwin Park, CA23 studi
- Chicago, IL22 studi
Altri studi a Birmingham
- Cancro (tutti i tipi)30 studi
- Cancro al seno24 studi
- Obesità23 studi
- Cancro ovarico23 studi
- Cancro del polmone non a piccole cellule22 studi
- Leucemia mieloide acuta21 studi
- BPCO17 studi
- Malattie cardiovascolari17 studi
- Sovrappeso16 studi
- Cancro dell'endometrio16 studi
- Diabete di tipo 216 studi
- Fibrosi cistica16 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.